Pricing confirmed during consultationBPC-157/TB-500 $269 Semax Cognitive Support Focus, mental clarity, and cognitive support goals are discussed after the provider evaluates health history, medications, and fit
Zepbound (tirzepatide) returning as additional CVS Caremark preferred option (10/1/2026) Zepbound (tirzepatide, FDA-approved for weight loss) is returning as an additional preferred weight-loss option on CVS Caremark effective October 1, 2026
The latest dual-action GLP-1 analogue, tirzepatide , which also affects GIP receptors, was approved in the US in 2022 as the drug Mounjaro for the treatment of type 2 diabetes, and in 2023 as Zepbound for the treatment of obesity and excess weight, as well as obstructive sleep apnea syndrome in obese individuals
Important Safety Information: Handle only by qualified laboratory personnel using appropriate safety procedures
We are committed to providing compassionate care and long-term support to help you achieve and maintain a healthier weight
Modulation of CPT-1 may affect energy metabolism and food intake, and research is ongoing into the effects of both stimulation and inhibition of CPT-1 and in relation to obesity management [74]